Connection

Mohamad Mohty to Adolescent

This is a "connection" page, showing publications Mohamad Mohty has written about Adolescent.
Connection Strength

0.260
  1. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019 11; 54(11):1815-1826.
    View in: PubMed
    Score: 0.023
  2. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. JAMA Oncol. 2018 09 01; 4(9):1245-1253.
    View in: PubMed
    Score: 0.022
  3. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. Biol Blood Marrow Transplant. 2018 07; 24(7):1471-1475.
    View in: PubMed
    Score: 0.021
  4. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003 Jul 15; 102(2):470-6.
    View in: PubMed
    Score: 0.007
  5. Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Ann Hematol. 2019 Oct; 98(10):2389-2398.
    View in: PubMed
    Score: 0.006
  6. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation. Eur J Haematol. 2019 Jul; 103(1):10-17.
    View in: PubMed
    Score: 0.006
  7. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):506-508.
    View in: PubMed
    Score: 0.006
  8. Fertility preservation from the point of view of hematopoietic cell transplant specialists-a worldwide-web-based survey analysis. Bone Marrow Transplant. 2019 11; 54(11):1747-1755.
    View in: PubMed
    Score: 0.006
  9. Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2019 09; 54(9):1499-1510.
    View in: PubMed
    Score: 0.006
  10. Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2019 01; 106:212-219.
    View in: PubMed
    Score: 0.005
  11. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018 10; 93(10):1236-1244.
    View in: PubMed
    Score: 0.005
  12. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2018 11; 183(3):411-420.
    View in: PubMed
    Score: 0.005
  13. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol. 2018 10; 93(10):1211-1219.
    View in: PubMed
    Score: 0.005
  14. Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation. Clin Infect Dis. 2018 08 01; 67(4):564-572.
    View in: PubMed
    Score: 0.005
  15. Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):515-526.
    View in: PubMed
    Score: 0.005
  16. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018 08 16; 132(7):750-754.
    View in: PubMed
    Score: 0.005
  17. Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. Am J Hematol. 2018 07; 93(7):859-866.
    View in: PubMed
    Score: 0.005
  18. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018 06; 53(6):683-691.
    View in: PubMed
    Score: 0.005
  19. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2018 06; 96:73-81.
    View in: PubMed
    Score: 0.005
  20. Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biol Blood Marrow Transplant. 2018 07; 24(7):1406-1414.
    View in: PubMed
    Score: 0.005
  21. Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. Bone Marrow Transplant. 2018 10; 53(10):1295-1303.
    View in: PubMed
    Score: 0.005
  22. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. Clin Cancer Res. 2018 06 15; 24(12):2794-2803.
    View in: PubMed
    Score: 0.005
  23. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018 03 15; 11(1):40.
    View in: PubMed
    Score: 0.005
  24. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol. 2018 04; 181(1):86-96.
    View in: PubMed
    Score: 0.005
  25. Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia. Am J Hematol. 2018 05; 93(5):635-642.
    View in: PubMed
    Score: 0.005
  26. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 2018 04 01; 124(7):1428-1437.
    View in: PubMed
    Score: 0.005
  27. Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplant. 2018 04; 53(4):422-430.
    View in: PubMed
    Score: 0.005
  28. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Am J Hematol. 2018 03; 93(3):416-423.
    View in: PubMed
    Score: 0.005
  29. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 04; 24(4):751-757.
    View in: PubMed
    Score: 0.005
  30. Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017 12; 102(12):2134-2140.
    View in: PubMed
    Score: 0.005
  31. Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission. Am J Hematol. 2017 Dec; 92(12):1318-1323.
    View in: PubMed
    Score: 0.005
  32. An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. Clin Cancer Res. 2017 Nov 01; 23(21):6478-6486.
    View in: PubMed
    Score: 0.005
  33. Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017 Oct; 92(10):997-1003.
    View in: PubMed
    Score: 0.005
  34. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. J Hematol Oncol. 2017 06 21; 10(1):128.
    View in: PubMed
    Score: 0.005
  35. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. Am J Hematol. 2017 Aug; 92(8):789-796.
    View in: PubMed
    Score: 0.005
  36. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. Am J Hematol. 2017 Jul; 92(7):653-659.
    View in: PubMed
    Score: 0.005
  37. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer. 2017 Aug 01; 123(15):2867-2874.
    View in: PubMed
    Score: 0.005
  38. Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017 06; 102(6):1066-1074.
    View in: PubMed
    Score: 0.005
  39. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. Cancer. 2017 06 01; 123(11):1965-1970.
    View in: PubMed
    Score: 0.005
  40. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. J Hematol Oncol. 2017 01 24; 10(1):31.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.